Search results for "Coronavirus"
CDC recommendations on COVID-19 vaccine boosters, new data on vaccine effectiveness
Several groups in the U.S. are now eligible to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after completing the initial two-dose series.
https://immattersacp.org/weekly/archives/2021/09/28/1.htm
28 Sep 2021
Register now for next ACP, Annals of Internal Medicine forum on COVID-19
On Oct. 8, panelists will provide insight on the clinical implications of the immunology of SARS-CoV-2 and the COVID-19 vaccine, including the status of booster doses and the efficacy of vaccination in various groups.
https://immattersacp.org/weekly/archives/2021/10/05/2.htm
5 Oct 2021
Studies find monoclonal antibodies and remdesivir effective, while vaccine-associated myocarditis is rare
A trial of casirivimab plus imdevimab indicated it reduced risk of hospitalization or death, the CDC urged vaccination during pregnancy and updated its v-safe tool, and an analysis showed that postvaccine myocarditis occurred in men and resolved with conservative treatment.
https://immattersacp.org/weekly/archives/2021/10/05/1.htm
5 Oct 2021
Boosters, antithrombotic therapy, mental health effects, more COVID-19 news
FDA advisors recommended booster administration for the Moderna vaccine for certain populations, an ACP/Annals forum covered the immunology of SARS-CoV-2, a trial showed that neither aspirin nor apixaban benefited outpatients with COVID-19, and ACP partnered with YouTube to combat medical misinformation related to COVID-19.
https://immattersacp.org/weekly/archives/2021/10/19/2.htm
19 Oct 2021
More booster authorizations, research on vaccine safety and uptake
The FDA and CDC endorsed boosters of the Johnson & Johnson and Moderna vaccines. Recent research showed that COVID-19 vaccination was not associated with miscarriage, and a small financial incentive for receiving a COVID-19 vaccine or providing transportation to a vaccination site increased uptake.
https://immattersacp.org/weekly/archives/2021/10/26/1.htm
26 Oct 2021
Regulatory changes for COVID-19 vaccine; data on waning immunity, outpatient therapies
The FDA authorized vaccinating children, the NIH supported concurrent use of flu and COVID-19 shots, and the CDC addressed a fourth dose of COVID-19 vaccine for the immunocompromised. Trials found benefit from a new monoclonal antibody and an old antidepressant for high-risk outpatients.
https://immattersacp.org/weekly/archives/2021/11/02/1.htm
2 Nov 2021
New research on booster doses, breakthrough infections, long-term COVID-19 symptoms
A vaccine booster significantly reduced risk of severe disease or death from COVID-19, full vaccination provided more protection than previous infection, many patients reporting persistent symptoms did not have antibodies to SARS-CoV-2, and a trial of outpatient treatment was ineffective, recent studies found.
https://immattersacp.org/weekly/archives/2021/11/09/1.htm
9 Nov 2021
Monitoring outpatients by text appeared to reduce mortality from COVID-19
Patients with SARS-CoV-2 who received twice-daily, automated text message check-ins with an option to report worsening symptoms at any time had lower 30- and 60-day mortality than outpatients receiving usual care, a retrospective study found.
https://immattersacp.org/weekly/archives/2021/11/16/1.htm
16 Nov 2021
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum VII: Challenging Clinical Questions
During the Dec. 8 virtual live event, a panel of experts will provide answers to common questions about COVID-19 that physicians face today.
https://immattersacp.org/weekly/archives/2021/11/23/2.htm
23 Nov 2021
Q&A with ACP's President on COVID-19 vaccines
George M. Abraham, MD, MPH, MACP, ACP's President, recently discussed the difference between third shots and boosters and other complexities of vaccination, as well as offered advice to internists on getting more patients vaccinated.
https://immattersacp.org/weekly/archives/2021/11/23/1.htm
23 Nov 2021